New Peptide Therapy Shows Promise Against Glioblastoma Recurrence

Peptide binder design with inverse folding and protein structure prediction

The computational design of peptide binders towards a specific protein interface can aid diagnostic and therapeutic efforts. Here, we design peptide binders by combining the known structural space searched with Foldseek, the protein design method ESM-IF1, and AlphaFold2 (AF) in a joint framework. Foldseek generates backbone seeds for a modified version of ESM-IF1 adapted to protein complexes. The resulting sequences are evaluated with AF using a…

Researchers find promise in a new peptide drug to combat a deadly brain cancer

A lab-designed molecule developed and extensively studied could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer.

New peptide therapy shows promise against glioblastoma recurrence

A lab-designed molecule developed and extensively studied by scientists with Virginia Tech's Fralin Biomedical Research Institute at VTC could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer.

Lab-Designed Peptide Targets Glioblastoma Stem Cells

A newly developed lab-designed molecule, JM2, may offer a promising therapy to combat glioblastoma recurrence by targeting the tumor’s most resilient cells. Researchers discovered that glioblastoma stem cells rely on the protein connexin 43’s interaction with microtubules—an interaction disrupted by JM2.

Scientists Find Promise in a New Peptide Drug to Combat a Deadly Brain Cancer

A lab-designed molecule developed and extensively studied by scientists with Virginia Tech's Fralin Biomedical Research Institute at VTC could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer.